PeptideLabs Logo
PeptideLabs
Documentación de Calidad
Back to all 64 profiles
Community/research information onlyNo aprobado por FDA/EMA

Community protocol · LL-37

LL-37: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: LL37 · Human cathelicidin

Sources checked: 27 August 2026

Aviso importante de seguridad y responsabilidad

Esta página documenta y evalúa información de comunidades. No es consejo médico ni terapéutico, asesoramiento individual ni invitación al uso.

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

LL-37

Forma parte de la inmunidad innata; se estudian señales antimicrobianas, inflamatorias y de reparación.

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amounts, timing and cycles

Community/research information only

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amount status

Different amounts circulate online; no regulator-confirmed safe or effective dose exists.

Profile evidence level: preclinical.

Timing

Community claims about time of day, fasting windows or training intervals are not validated clinical standards.

No individual recommendation.

Cycle/duration

Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Reconstitución y conversión U-100

Calculadora de reconstitución

For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.

Calculadora de reconstitución

Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.

Concentration

3,333.33 µg/ml

Calculated volume

0.06 ml

U-100 units

6 U

Calculated portions per vial

50

Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.

Mechanism and research questions

Endogenous antimicrobial host-defence peptide

LL-37 is classified as “Endogenous antimicrobial host-defence peptide”. Forma parte de la inmunidad innata; se estudian señales antimicrobianas, inflamatorias y de reparación. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Defensa antimicrobiana del huésped

Los investigadores estudian cómo un péptido defensivo natural ataca a las bacterias y afecta las señales de inflamación, de forma similar a una primera línea de defensa de la piel y las mucosas. Se miden el crecimiento bacteriano y los marcadores inmunitarios en el laboratorio.

02

Péptido inmunomodulador

Esto estudia cómo un péptido ajusta la actividad de las células inmunitarias, de forma similar a un regulador que refuerza o atenúa la respuesta inmunitaria. Se miden los recuentos de células inmunitarias y los marcadores de inflamación en los estudios.

03

Péptido de migración celular

Esto estudia cómo un péptido influye en la migración de las células hacia un sitio de lesión, de forma similar a los trabajadores que se apresuran a una obra. Se miden la velocidad y el alcance de la migración celular en modelos de laboratorio.

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Anécdotas de salud intestinal

Las personas reportan mejoras digestivas percibidas subjetivamente tras usar péptidos gastroprotectores o inmunomoduladores, generalmente sin diagnósticos objetivos. Estas autoobservaciones no establecen un efecto confirmado sobre el intestino.

Anécdotas de cicatrización de heridas

Las personas reportan una curación percibida más rápida de lesiones o problemas de tendones tras usar ciertos péptidos, generalmente sin un grupo de control ni medición objetiva. Estos informes individuales no establecen una eficacia o seguridad reales.

Discusión de origen y pureza

Se discute qué proveedores se consideran más confiables y cómo difieren los resultados de las pruebas de pureza entre lotes. Estas evaluaciones comunitarias se basan en muestras limitadas y no reemplazan las pruebas de laboratorio independientes de cada lote individual.

Adverse effects and risk boundaries

  • Modular señales inmunes o antimicrobianas puede afectar inflamación, hipersensibilidad, riesgo de infección y respuestas imprevisibles; importan vía y formulación.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • Enfermedad autoinmune, trasplante, inmunosupresión, infección activa, cáncer y embarazo requieren valoración especializada.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Según la indicación pueden ser relevantes hemograma, inflamación, signos de infección, hígado/riñón y parámetros inmunes; no existe esquema comunitario universal.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Preclínico

Los efectos antimicrobianos e inflamatorios siguen en estudio, sin un uso clínico confirmado.

Published evidence

Los datos disponibles provienen principalmente de modelos animales o celulares; faltan datos sólidos de eficacia y seguridad en humanos.

LL-37 pertenece a la defensa inmunitaria innata, lo que la distingue de péptidos inmunitarios de acción adaptativa como la timosina alfa-1.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

No aprobado por FDA/EMA

No existe medicamento aprobado por FDA o EMA; eficacia y seguridad no están establecidas.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile